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Background: A higher risk of atherothrombotic cardiovascular events, which are platelet-driven 
processes, has been described during acute exacerbations of chronic obstructive pulmonary 
disease (AECOPD). However, the relevance of platelet reactivity during AECOPD and whether 
this is affected by antiplatelet agents are not fully elucidated to date. This study aimed to evalu-
ate whether platelet reactivity is augmented during an exacerbation in COPD patients with and 
without antiplatelet therapy and its association with systemic inflammatory parameters.
Materials and methods: Prospective, observational, ex vivo investigation was conducted in 
consecutive patients suffering an exacerbation of COPD. Platelet reactivity was assessed during 
AECOPD and at stable state. Platelet function assays included: 1) vasodilator-stimulated phos-
phoprotein assay expressed as P2Y
12
 reactivity index (PRI), 2) multiple electrode aggregometry 
and 3) optical aggregometry. Systemic inflammatory parameters such as leukocyte count, 
interleukin-6 and fibrinogen were also assessed.
Results: Higher platelet reactivity was observed during AECOPD compared to stability mea-
sured by vasodilator-stimulated phosphoprotein (PRI: 75.2%±1.9% vs 68.8%±2.4%, p=0.001). 
This augmented platelet aggregability was also observed in the subset of patients on antiplatelet 
therapy (PRI: 72.8%±3.1% vs 61.7%±7.5%, p=0.071). Consistent findings were observed with 
all other platelet function tests. Patients with greater enhancement of inflammatory markers 
during AECOPD were more likely to present a higher increase in platelet reactivity.
Conclusion: Platelet reactivity is increased during AECOPD, which may contribute to the 
augmented cardiovascular risk of these patients. Additionally, the increase in platelet reactivity 
might be associated with an increment in inflammatory markers during exacerbations.
Keywords: airflow limitation, inflammation, platelet aggregation, antiplatelets agents, 
thrombosis
Introduction
Cardiovascular disease is the most important comorbidity associated with chronic 
obstructive pulmonary disease (COPD) due to its impact on overall prognosis including 
mortality.1–3 Systemic inflammation has been suggested as one of the main factors that 
play a significant role in the pathogenesis of atherothrombosis in COPD,4,5 which is 
characterized by the presence of low-grade systemic inflammation in the stable state6 
and, noteworthy, by an acute inflammatory response during exacerbations of the 
disease, as shown by Thomsen et al.7 The increased systemic inflammation associ-
ated with acute exacerbations is of particular relevance since it can be an underlying 
mechanism that may contribute to the impaired cardiovascular outcomes observed in 
COPD patients. In line with this, atherothrombotic complications such as myocardial 
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infarction or stroke are particularly augmented during an 
acute exacerbation of COPD (AECOPD).8,9
Platelets are key elements in the development of athero-
sclerosis and its atherothrombotic complications.10 Several 
studies have observed that systemic inflammation may 
contribute to platelet activation and, thus, to an increased 
cardiovascular risk.11,12 In addition, an interesting mecha-
nistic investigation by Maclay et al has shown increased 
platelet activation in COPD patients compared to non-COPD 
subjects, and during AECOPD compared to stability.13 
However, the magnitude of the increment in platelet reac-
tivity during an AECOPD is not fully elucidated to date, 
and if this is affected by antiplatelet agents has not been 
previously evaluated. The aim of this study was to evaluate 
whether platelet reactivity is augmented during an AECOPD 
compared with stability in COPD patients with and without 
antiplatelet therapy (APT) and its possible association with 
systemic inflammatory parameters.
Materials and methods
Population and study design
This was a prospective, ex vivo, observational investigation 
conducted in consecutive COPD patients attended during an 
exacerbation at the pulmonology day hospital from a tertiary 
centre. All patients were between 40 and 80 years of age and 
had been diagnosed of COPD following Global initiative 
for chronic Obstructive Lung Disease recommendations.1 
An AECOPD was defined as an acute event character-
ized by worsening of the patient’s respiratory symptoms 
that is beyond normal day-to-day variations, which leads 
to a change in medication.1 Exacerbations were classified 
as moderate (outpatient treatment requiring antibiotics 
and/or oral corticosteroids) and severe (requiring hospital 
admission).14 Exclusion criteria were the presence of other 
pulmonary disease, current therapy with anticoagulant agents 
or glycoprotein IIb/IIIa inhibitors, any active malignancy or 
hematologic disease, platelet count 100×106/µL, severe 
chronic kidney disease (creatinine clearance 30 mL/min) 
and pregnant females. Patients could receive APT with 
aspirin or clopidogrel for concomitant chronic cardiovascular 
conditions.
The study had a prospective design with paired data, in 
which assessments were performed at two time points: the 
first one during AECOPD and the second one after the patient 
had recovered stability (4–6 weeks after the first visit and no 
symptoms of exacerbation or administration of antibiotics or 
oral corticosteroids for at least 2 weeks). In patients receiving 
APT, blood samples were collected for platelet function 
testing before the daily maintenance dose of aspirin or 
clopidogrel was administered. The study was approved by the 
local ethics committee “Comitè Ètic d’ Investigació Clínica 
Del Hospital de Bellvitge”, No PR077/13, and performed 
in accordance with the Declaration of Helsinki. All subjects 
provided written informed consent to the study.
Platelet function assays
Blood samples were collected from antecubital vein, dis-
carding the first 2–4 mL of blood to avoid spontaneous 
platelet activation. Samples were processed by trained labora-
tory personnel blinded to the patient status and medication 
within 2 hours of blood drawing. Several agonists were used 
in platelet function assessments in order to explore different 
platelet activation signaling pathways. In patients receiving 
APT, aspirin-mediated effects were specifically evaluated 
by using arachidonic acid and collagen as agonists, while 
clopidogrel-mediated effects were specifically assessed by 
using adenosine diphosphate (ADP) as an agonist. Platelet 
function assays included flow cytometric analysis of the 
phosphorylation status of vasodilator-stimulated phosphop-
rotein (VASP), light transmission aggregometry (LTA) and 
multiple electrode aggregometry.
analysis of the phosphorylation status of  VasP
The P2Y
12
 reactivity index (PRI) measures the functional 
status of the platelet P2Y
12
 signaling pathway and was 
determined according to standard protocols.15 In brief, VASP 
phosphorylation (VASP-P) was measured by quantitative 
flow cytometry using commercially available labeled mono-
clonal antibodies (Biocytex Inc., Marseille, France). The 
PRI was calculated after measuring the mean fluorescence 
intensity (MFI) of VASP-P levels following challenge with 
prostaglandin E1 (PGE1) and PGE1 + ADP. PGE1 increases 
the VASP-P levels through stimulation of adenylate cyclase, 
and ADP binding to purinergic receptors leads to inhibition 
of adenylate cyclase; thus, the addition of ADP to PGE1-
stimulated platelets reduces the levels of PGE1-induced 
VASP-P. The PRI was calculated as follows: ([MFI PGE1]-
[MFI PGE1 + ADP]/[MFI PGE1]) ×100%. An increased PRI 
is indicative of higher platelet reactivity.
lTa
LTA was performed according to standard protocols as 
previously described.16 Briefly, blood-citrate tubes were cen-
trifuged at 100× g for 10 min to recover platelet-rich plasma 
(PRP) and further centrifuged at 2,400× g for 15 min to 
recover platelet-poor plasma (PPP). Platelet aggregation was 
assessed using PRP and PPP by the turbidometric method 
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Platelet reactivity in acute exacerbations of COPD
Chrono-Log Corp., Havertown, PA, USA). Light transmis-
sion was adjusted to 0% for PRP and 100% for PPP for 
each measurement. Maximal platelet aggregation is reported 
as a percentage and was measured following stimuli with 
several agonists: ADP (5 and 20 µmol/L), arachidonic acid 
(1 mmol/L) and collagen (2 µg/mL).
Multiple electrode aggregometry
Blood was collected in hirudin-treated tubes. Multiple 
electrode aggregometry was performed in whole blood 
with the Multiplate™ analyzer (Hoffman-La Roche Ltd., 
Basel, Switzerland) as previously described.17 This instru-
ment assesses the change in impedance caused by the 
adhesion of platelets onto sensor units formed by silver-
covered electrodes. In this investigation, the following 
agonists were used: ADP (6.4 µmol/L), arachidonic acid 
(0.5 mmol/L), collagen (3.2 µg/mL) and thrombin receptor 
activating peptide (32 µmol/L). Aggregation curves were 
recorded for 6 min and platelet aggregation was determined 
as the area under the curve of arbitrary aggregation units 
(AU × min).
Systemic inflammatory parameters
Three inflammatory parameters involved in COPD exacerba-
tions were assessed: leukocyte count, interleukin-6 (IL-6) and 
fibrinogen.7 Leukocytes were measured as part of complete 
cell blood counts performed at the time points described 
above. To quantify the IL-6 (expressed in pg/mL) and fibrino-
gen (expressed in g/L) serum levels, individual enzyme-
linked immunosorbent assay tests were used following the 
manufacturer’s instructions. The lower limit of detection 
for IL-6 was 0.156 pg/mL (HS600B; R&D Systems, Inc., 
Minneapolis, MN, USA) and for fibrinogen was 1.56 ng/mL 
(ab208036; Abcam, Cambridge, UK).
study endpoints and sample size
The primary endpoint of this study was the difference in 
platelet reactivity measured as PRI of COPD patients during 
the AECOPD compared to stable state. Assuming an SD of 
20%, a sample size of 36 subjects was needed to detect a 
minimal difference between time points of 10%, with 85% 
power and a two-tailed p-value 0.05 for a paired data 
comparison. Considering an approximate 10% dropout rate 
(eg, inadequate samples or loss in the follow-up), the inclu-
sion of 40 subjects was allowed to ensure that data from 
36 patients were available for analysis. The secondary end-
points included: 1) differences in platelet reactivity measured 
with the other platelet function assays during the AECOPD 
compared to stable state and 2) changes in inflammatory 
parameters during the AECOPD compared to stable state 
and their association with platelet reactivity.
statistical analysis
Conformity to the normal distribution was evaluated for 
continuous variables with the Kolmogorov–Smirnov and the 
Shapiro–Wilk tests. For baseline characteristics, categorical 
variables were expressed as frequencies and percentages, 
whereas continuous variables were summarized by mean ± SD 
or by median (interquartile range) if a normal distribution 
could be assumed or not, respectively. A repeated-measures 
analysis of variance (ANOVA) model was used to evaluate 
the primary endpoint and to make all other intragroup com-
parisons between the AECOPD compared to the stable state. 
In order to evaluate the association between inflammation 
and platelet aggregability, exploratory analyses comparing 
the change in platelet reactivity measured by VASP (ΔPRI: 
PRI during exacerbation–PRI during stability) according to 
tertiles of the difference (Δ) of each inflammatory marker 
(levels during exacerbation–levels during stability) were 
performed using an ANOVA method with a general linear 
model. Results are reported as least squares mean ± standard 
error of the mean for the above-detailed ANOVA analyses. 
A p-value 0.05 was considered statistically significant for 
all comparisons. Statistical analysis was performed using 
SPSSv18.0 software (SPSS Inc., Chicago, IL, USA).
Results
Forty consecutive severe COPD patients consulting with 
an AECOPD were prospectively included. Two patients 
were excluded because they were lost in the follow-up, and 
one patient was excluded because anticoagulant therapy 
for atrial fibrillation was prescribed before visit 2 occurred. 
Therefore, a total of 37 patients were included in this analysis: 
29 (78.4%) with a moderate AECOPD and 8 (21.6%) with 
a severe AECOPD, thus requiring admission. In this cohort, 
10 patients receiving APT were included: 8 on aspirin and 
2 on clopidogrel. Demographic and clinical characteristics 
of the overall population are summarized in Tables 1 and 2. 
Characteristics of the AECOPD as well as treatment approach 
are listed in Table 3.
Platelet reactivity during an aeCOPD
Higher platelet reactivity was observed during AECOPD 
compared to stability, as measured by VASP (PRI: 75.2%± 
1.9% vs 68.8%±2.4%, p=0.001) in the overall sample 
(Figure 1). Consistent results were obtained with the other 
platelet function assays performed and all agonists used, 
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during exacerbations, although statistical significance was 
not reached in all of them (Table 4).
The increase in platelet reactivity during exacerbations 
was consistent in patients with or without concomitant APT. 
In patients not receiving APT, a statistically significant 
greater PRI was observed during AECOPDs compared to 
stability (76.0%±1.5% vs 71.2%±2.0%, p=0.007; Figure 1), 
with parallel findings obtained with the other platelet function 
tests used (Table 4).
A numerically higher platelet reactivity was seen during 
exacerbations in the subset of patients with APT, although 
not achieving statistical significance (PRI: 72.8%±3.1% vs 
61.7%±7.5%, p=0.071; Figure 1). Among those receiving 
aspirin (n=8), a higher collagen-induced platelet aggrega-
tion measured with LTA was observed during AECOPD 
(56.2%±6.1% vs 43.8%±6.4%, p=0.022), whereas the 
numerical differences did not reach statistical significance 
with the other assays sensitive to aspirin therapy (data not 
shown). In the two patients on clopidogrel, no differences 
in platelet reactivity were observed during exacerbations 
compared to stability (data not shown).
Systemic inflammatory parameters
The levels of all inflammatory parameters assessed were 
augmented during AECOPD compared to the stable state 
(Figure 2): leukocytes (8.8±0.5 vs 7.3±0.4×109/L, p=0.001), 
IL-6 (5.7±0.8 vs 3.0±0.4 pg/mL, p=0.002) and fibrinogen 
(5.5±0.7 vs 4.7±0.8 g/L, p=0.021).
The change in platelet reactivity measured by VASP 
was numerically higher in those patients in whom a greater 
difference in the levels of inflammatory markers between 
exacerbation and stability was observed. The most evident 
and almost statistically significant association was found 
between ΔPRI and Δleukocyte count split into tertiles (lower 
tertile: -0.5%±3.4%, mid tertile: 7.2%±3.2%, upper tertile: 
9.0%±3.2%; p for trend 0.051; Figure 3), while the associa-
tion was less marked for IL-6 and fibrinogen (p for trend 
0.072 and 0.227, respectively; Figure 3).
Discussion
In this investigation, we evaluated the impact of an acute 
exacerbation on platelet reactivity in COPD patients with a 
comprehensive panel of assays in order to explore different 
Table 1 Demographic and clinical characteristics
N=37
age (years), mean ± sD 69.8±5.7
Male, n (%) 35 (94.6)
Body mass index (kg/m2), mean ± sD 27.7±5.1
risk factors and medical history
Current smoking, n (%) 4 (10.8)
Pack-years, median (IQr) 45.0 (37.0–68.5)
hypertension, n (%) 22 (59.5)
Diabetes mellitus, n (%) 4 (10.8)
Dyslipidemia, n (%) 16 (43.2)
Coronary heart disease, n (%) 5 (13.5)
Chronic heart failure, n (%) 6 (16.2)
Osas, n (%) 7 (18.9)
Previous stroke, n (%) 2 (5.4)
Peripheral vascular disease, n (%) 2 (5.4)
Abbreviations: IQr, interquartile range; Osas, obstructive sleep apnea syndrome.




FeV1 post-bronchodilator % predicted,  
median (IQr)
38.6 (30.0–45.5)
FeV1/FVC post-bronchodilator, median (IQr) 38.5 (35.4–45.7)
Medical therapy
aspirin, n (%) 8 (21.6)
Clopidogrel, n (%) 2 (5.4)
statins, n (%) 14 (37.8)
PPI, n (%) 24 (64.9)
Oral antidiabetic agents/insulin, n (%) 4 (10.8)/2 (5.4)
aCeIs/arBs, n (%) 15 (40.5)
Beta-blockers, n (%) 4 (10.8)
Calcium antagonists, n (%) 6 (16.2)
CPaP, n (%) 6 (16.2)
Oxygen at home, n (%) 15 (40.5)
laboratory data
hemoglobin (g/l) 137 (126–150)
Platelet count (×109/l) 246.0 (186.5–301.0)
glucose (mmol/l) 5.6 (5.1–7.2)
Creatinine (µmol/l) 72.0 (62.0–91.0)
Abbreviations: aCeIs, angiotensin converting enzyme inhibitors; arBs, angio-
tensin II receptor blockers; CPaP, continuous positive airway pressure; FeV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; IQr, interquartile range; 
PPIs, proton pump inhibitors.
Table 3 Characteristics of the acute exacerbations
N=37
severity of current exacerbation
Moderate, n (%) 29 (78.4)
severe, n (%) 8 (21.6)
Days of worsening symptoms, median (IQr) 4.0 (3.0–7.0)
ph, median (IQr) 7.41 (7.39–7.42)
PaO2 (mmhg), median (IQr) 69.0 (64.8–74.3)
PaCO2 (mmhg), median (IQr) 44.0 (39.0–50.5)
Positive culture to bacterial infection, n (%) 26 (70.3)
Virus isolation, n (%) 1 (2.7)
requirements of systemic corticosteroids, n (%) 36 (97.3)
requirements of antibiotics, n (%) 34 (91.9)
requirements of hospitalization, n (%) 8 (21.6)

















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Platelet reactivity in acute exacerbations of COPD
platelet signaling pathways. Noteworthy, patients receiving 
APT were not excluded, expanding upon prior studies by 
evaluating the impact of these agents on the results. The 
main findings of this study can be summarized as follows: 
1) platelet reactivity is increased during AECOPD; 2) this 
augmented platelet aggregability is also observed in patients 
on APT and 3) those patients with greater enhancement of 
inflammatory markers during an AECOPD are more likely 
to present a higher increase in platelet reactivity.
Cardiovascular disease is the leading cause of mortality 
in COPD patients when respiratory failure is excluded.18 
In fact, prior investigations have observed that COPD 
subjects have an increased risk of ischemic heart disease irre-
spective of age, gender or smoking status.19–22 Remarkably, 
a 2–3-fold increased risk of myocardial infarction has been 
described during the first 5 days following an AECOPD,8 
which underscores the need for a better understanding of 
the mechanisms linking AECOPD, inflammation and car-
diovascular atherothrombotic complications. Few studies 
have previously evaluated and observed augmented platelet 
activation in COPD patients compared to control subjects.23–26 
Further, the impact of an AECOPD in platelet reactivity has 
been only evaluated in a single experience by Maclay et al 
who demonstrated increased circulating platelet–monocyte 
aggregates and, thus, higher platelet reactivity during exac-
erbations compared to stable COPD.13 In line with this, our 
investigation confirmed that exacerbations of COPD lead to 
a hyperreactive platelet phenotype, showing upregulation 
of multiple signaling pathways. Noteworthy, this is the first 
study evaluating the impact of AECOPD on platelet reactivity 
with platelet function assays with proven ability to predict 
clinical outcomes in patients with ischemic heart disease.27
Table 4 Platelet reactivity during the acute exacerbation and stable state
Test Overall population, N=37 No antiplatelet therapy, N=27
Exacerbation Stable state p-value Exacerbation Stable state p-value
VasP
PrI (%) 75.2±1.9 68.8±2.4 0.001 76.0±1.5 71.2±2.0 0.007
lTa
MPa aDP-5 µmol/l (%) 64.2±3.4 60.6±3.6 0.076 68.7±3.5 64.1±4.2 0.069
MPa aDP-20 µmol/l (%) 69.0±2.9 67.4±2.9 0.461 72.5±2.6 69.1±2.8 0.177
MPa aa-1 µmol/l (%) 54.9±6.2 54.0±6.0 0.459 72.8±1.2 71.2±1.7 0.328
MPa Coll-2 µmol/l (%) 72.6±2.5 66.4±3.2 0.001 78.3±1.3 73.9±1.8 0.009
Mea
aDP (aU × min) 749.6±41.3 636.4±39.3 0.001 824.5±33.5 707.6±41.5 0.007
Coll (aU × min) 755.4±40.5 672.51±41.6 0.028 1,049.9±60.5 1,005.3±65.1 0.393
aa (aU × min) 786.0±65.4 731.28±64.9 0.124 948.3±49.0 871.6±48.4 0.067
TraP (aU × min) 1,048.9±55.8 1,006.3±57.5 0.383 767.4±44.3 648.7±42.7 0.001
Notes: Platelet reactivity was measured with different platelet function assays in the overall population and in the cohort of patients not receiving antiplatelet therapy. Values 
are expressed as least squares mean ± seM. The p-values were obtained using repeated-measures analysis of variance.
Abbreviations: aa, arachidonic acid; aDP, adenosine diphosphate; aU, area under the curve; Coll, collagen; lTa, light transmission aggregometry; Mea, multiple 






























































Figure 1 Platelet reactivity measured by VasP assay.
Notes: Black lines represent the least squares mean of the groups. (A) Overall population, (B) subset of patients without antiplatelet therapy, (C) subset of patients under 
antiplatelet therapy.
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It has been reported that COPD patients suffering a 
myocardial infarction have worse prognosis than non-
COPD patients.28 This can be partially explained by the 
fact that COPD patients are less likely to receive guideline-
recommended secondary preventive medications with proven 
benefit, such as antiplatelet agents.28 Another important fea-
ture of our investigation is that patients receiving APT were 
also included in the study, whereas they were specifically 
excluded in prior experiences. The finding that patients receiv-
ing APT with aspirin or clopidogrel also displayed increased 
platelet reactivity during an AECOPD raises questions about 
the efficacy of these two agents in this setting and suggests 
that a more potent antiplatelet drug could be of help for COPD 
patients in certain scenarios. Moreover, the results of a recent 
post hoc analysis of a randomized large-scale trial showed that 
ticagrelor, a very potent platelet P2Y
12
 inhibitor, was more 
effective in terms of reducing the risk of ischemic events than 
clopidogrel (both in addition to aspirin) in COPD patients 
with an acute coronary syndrome.29 However, further clinical 
studies are required to consider if potent antiplatelet treatment 
must be used during exacerbations in COPD patients with 
concomitant ischemic cardiovascular diseases.
The exact underlying mechanisms of platelet activation 
in COPD patients have not been identified, although several 
factors have been suggested to contribute, such as increased 
systemic inflammation, hypoxemia and oxidative stress.30 In 
particular, COPD is characterized by the presence of low-
grade systemic inflammation and an acute inflammatory 
response during exacerbations of the disease.7,31 Moreover, 
the role of inflammation in the formation of atherosclerotic 
lesions and the occurrence of atherothrombotic complica-
tions, where platelets also play a key role, is undisputed.11,12 
In line with this idea, an association between leukocyte count 
and platelet reactivity has been previously reported.32 In our 
investigation, those patients with greater increment of inflam-
matory markers such as leukocyte count had a numerical 
trend towards larger increases in platelet reactivity without 
reaching statistical significance. This finding might support 
Figure 3 Association between the PRI and the inflammatory parameters.
Notes: The change in PRI was evaluated as the difference: PRI during AECOPD–PRI during stable state. The difference in the inflammatory parameters during AECOPD and 
stable state was divided into tertiles. (A) Difference (Δ) in plasma leukocyte count, (B) difference (Δ) in serum Il-6 and (C) difference (Δ) in serum fibrinogen.
Abbreviations: aeCOPD, acute exacerbations of chronic obstructive pulmonary disease; Il-6, interleukin-6; PrI, P2Y12 reactivity index.
A p for trend =0.051
Lower Mid
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Figure 2 Inflammatory parameters assessed during AECOPD compared to the stable state.
Notes: Black lines represent the least squares mean of the groups. (A) Plasma leukocyte count, (B) serum Il-6 and (C) serum fibrinogen.
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Platelet reactivity in acute exacerbations of COPD
the idea of an association between inflammation and platelet 
activation in COPD patients.
This study has several inherent limitations due to its 
observational design and relatively small sample size. 
However, the consistent findings obtained using a variety of 
assays and agonists are supportive of our study conclusions. 
The subset of patients receiving APT is particularly small, 
making the study underpowered to detect differences in this 
subgroup; therefore, results obtained in this subgroup should 
be considered exploratory and hypothesis generating. In addi-
tion, all patients included in our study had severe and very 
severe airway limitation, representing an advanced stage of 
the disease. Therefore, whether the findings of our study can 
be extrapolated to mild or moderate COPD patients cannot 
be ascertained.
Conclusion
Platelet reactivity is augmented during acute exacerba-
tions of COPD, irrespective of treatment with antiplatelet 
agents. This platelet hyperreactivity may contribute to the 
augmented cardiovascular risk of these patients. In addition, 
the increase in platelet reactivity could be directly associated 
with an increment in systemic inflammatory markers during 
exacerbations.
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